Samuel J. Reich currently serves as Chairman and CEO of SAB Biotherapeutics. He served as executive chairman of our board of directors since our business combination with Big Cypress Acquisition Corp in October 2021 and was elected CEO of SAB in January 2024.
Eddie J. Sullivan, PhD, is our co-founder and president since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining us, he held the CEO role or other leadership roles in our predecessor entities, including CEO of Hematech, a subsidiary of Kyowa
Katie Ellias joined SAB's Board of Directors in November 2023, bringing more than twenty years of health care and investment experience to SAB. Ms. Ellias serves as a Managing Director at the JDRF T1D Fund LLC, a venture philanthropy fund with approximately $200 million in assets, including an
Rear Admiral (RADM), retired, Scott Giberson joined the SAB board of directors in July, 2022. He is currently the President of AMI Expeditionary Healthcare, a private global healthcare solutions company where he fosters global client relations at the highest levels.
Christine Hamilton, MBA, is our co-founder and has served as a member of our board of directors since 2014. Ms. Hamilton is the co-owner and managing partner of Christiansen Land and Cattle, Ltd., a large diversified farming and ranching operation in central South Dakota, and is also the co-owner
Played a key role in national development of Standardized Performance Analysis (SPA) Co-Founder and member of the Board of Managers of BioDak, LLC Board member of MHCH Family Foundation Past President of the Farm Financial Standards Council Dr. Edward Hamilton is a large animal veterinarian and
Jae is the President and Chief Operating Officer of Sessa Capital, where he is responsible for all aspects of the firm not directly related to the investment decision making process. Prior to joining Sessa Capital in 2015, Jae was the COO and Partner at Mudrick Capital from 2012 to 2015.
David Link, MBA, has served as a member of our board of directors since 2018 and is currently Vice-Chairman. Mr. Link is the former executive vice president and chief strategy officer at Sanford Health with more than three decades of experience in strategy, planning and financial operations.
Erick Lucera, CFA joined the SAB board of directors in April 2023, bringing thirty years of financial, operational and investment experience in the biotechnology and medical device industry. Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused
Andrew Moin joined the SAB Board of Directors in October 2023, bringing over 15 years of expertise across investment management and law, and is a passionate supporter of the type 1 diabetes community. Mr. Moin is currently a Partner and Analyst at Sessa Capital, a New York based investment advisor
Dr. William J. Polvino, MD, has served as a member of our board of directors since 2019, after having served as our business advisor for several years. Dr. Polvino is pharmaceutical entrepreneur with more than 25 years of experience in the healthcare arena.
Dr. Jay S. Skyler, M.D., MACP, FRCP joined the Board in May 2024. He is a Professor of Medicine, Pediatrics and Psychology and Deputy Director of the Diabetes Research Institute at the University of Miami in Florida, where he has been employed since 1976. Dr.
Jeffrey G. Spragens has served as a member of our board of directors since November 2020. From 2005 through 2013, Mr. Spragens was a Co-Founder and the CEO of SafeStitch Medical, Inc., a medical device company that pioneered incisionless surgery techniques that helps to relieve GERD and obesity.
